MLT-943

• Description:

  MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC50 across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood) . MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research[1].

• UNSPSC:

  12352005

• Target:

  MALT1

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mlt-943.html

• Purity:

  99.77

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CO[C@H](C1=C(NC(NC2=CC=NC(C(F)(F)F)=C2)=O)C=NC3=CC(Cl)=NN13)C

• Molecular Formula:

  C16H14ClF3N6O2

• Molecular Weight:

  414.77

• References & Citations:

  [1]Kea Martin, et al. Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology. Front Immunol|[2]Jean Quancard, et al. Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood. J Med Chem. 2020 Dec 10;63 (23) :14594-14608.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1832576-04-1]